Impella RP Post-Approval Study Data Presented at ACC 2019 Data demonstrates survival benefit with the Impella RP Recover Right protocol The Impella RP FDA post-market study data shows 64% survival ...
NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Nasdaq:RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced it is developing its first adeno-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback